An evaluation of a Bayesian method of dose escalation based on bivariate binary responses

Journal of Biopharmaceutical Statistics

Volumn 14, Issue 4, 2004, Pages 969-983

  Whitehead, John ^a   Zhou, Yinghui ^a   Stevens, John ^b   Blakey, Graham ^b  

^a UNIVERSITY OF READING   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Bayesian decision procedure; Continual reassessment method; Dose escalation; Logistic regression; Phase I clinical trial

Indexed keywords

LEUKOTRIENE B4; NEW DRUG; PLACEBO;

ACCURACY; BAYES THEOREM; BRADYCARDIA; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG SAFETY; DYSPHONIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; LEUKOCYTE COUNT; LOGISTIC REGRESSION ANALYSIS; METHODOLOGY; MORTALITY; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; QT PROLONGATION; REVIEW; SIDE EFFECT; SIMULATION; VARIANCE; VOMITING;

ALGORITHMS; BAYES THEOREM; DOSE-RESPONSE RELATIONSHIP, DRUG; EVALUATION STUDIES; HUMANS; PHARMACEUTICAL PREPARATIONS; PNEUMONIA; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 9244230072     PISSN: 10543406     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIP-200035471     Document Type: Review

References (16)

1. Babb, J., Rogatko, A., Zacks, S. (1998). Cancer phase I clinical trials: Efficient dose escalation with overdose control. Statist. Med. 17:1103-1120.
2. Braun, T. M. (2002). The bivariate continual reassessment method: Extending the CRM to phase I trials of two competing outcomes. Control. Clin. Trials 23:240-256.
3. Paries, D. (1994). Practical modifications of the continual reassessment method for phase I cancer clinical trials. J. Biopharmaceutical Statist. 4:147-164.
4. Gasparini, M., Eisele, J. (2000). A curve-free method for phase I clinical trials. Biometrics 56:609-615.
5. Goodman, S. N., Zahurak, M. L., Piantadosi, S. (1995). Some practical improvements in the continual reassessment method for phase I studies. Statist. Med. 14:1149-1161.
6. Gooley, T. A., Martin, P. J., Fisher, L. D., Pettinger, M. (1994). Simulation as a design tool for phase I/II clinical trials: An example from bone-marrow transplantation. Control. Clin. Trials 15:450-462.
7. Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C., Simon, R. M. (1994). A comparison of two phase I designs. Statist. Med. 13:1799-1806.
8. O'Quigley, J. (2001). Dose-finding designs using continual reassessment method. In: Crowley, J., ed. Statistics in Clinical Oncology. New York: Dekker, pp. 35-72.
9. O'Quigley, J., Pepe, M., Fisher, L. (1990). Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46:33-48.
10. O'Quigley, J., Hughes, M. D., Fenton, T. (2001). Dose-finding designs for HIV studies. Biometrics 57:1018-1029.
11. Rosenberger, W. F., Haines, L. M. (2002). Competing designs for phase I clinical trials: A review. Statist. Med. 21:2757-2770.
12. Thall, P. F., Russell, K. E. (1998). A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 54:251-264.
13. Whitehead, J., Brunier, H. (1995). Bayesian decision procedures for dose determining experiments. Statist. Med. 14:885-893.
14. Whitehead, J., Williamson, D. (1998). An evaluation of Bayesian decision procedures for dose-finding studies. J. Biopharmaceutical Statist. 8:445-467.
15. Whitehead, J., Zhou, Y., Stevens, J., Blakey, G., Price, J., Leadbetter, J. (2004). Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit. Technical Report 04/3, School of Applied Statistics, University of Reading.
16. Zhou, Y., Whitehead, J. (2003). Practical implementation of Bayesian dose escalation procedures. Drug Inf. J. 37:45-59.